PMID- 25846031
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 16
IP  - 7
DP  - 2015 May
TI  - Switch from oral pramipexole or ropinirole to rotigotine transdermal system in 
      advanced Parkinson's disease: an open-label study.
PG  - 961-70
LID - 10.1517/14656566.2015.1030336 [doi]
AB  - OBJECTIVE: Investigate safety, feasibility and efficacy of switching therapy in 
      patients with advanced-stage Parkinson's disease (PD) inadequately controlled 
      with pramipexole (</= 3.5 mg/day) or ropinirole (</= 14 mg/day) to rotigotine 
      transdermal system (</= 14 mg/24 h; dose adjustments </= 16 mg/24 h permitted). 
      METHODS: PD0009 (ClinicalTrials.gov: NCT01711866) was an open-label study in 
      patients with advanced-stage PD receiving levodopa, and experiencing sleep 
      disturbance or early-morning motor impairment. Pramipexole/ropinirole was 
      switched to equivalent dose rotigotine overnight or in two stages. During the 
      4-week treatment period rotigotine dose adjustments were permitted (up to 16 
      mg/24 h). Primary variable: Clinical Global Impressions (CGI) item 4: side 
      effects (assessing safety) at end of treatment. RESULTS: 79/87 (91%) patients 
      completed the study; 2 (2%) withdrew due to adverse events (AEs). Most (84; 97%) 
      had CGI item 4 score < 3 indicating switch did not interfere with functioning; 
      three experienced drug-related AEs interfering with functioning (score = 3). 62% 
      patients improved on Patient Global Impression of Change, assessing 
      effectiveness. AEs occurring >/= 5%: application site pruritus (10%), application 
      site erythema (7%), dizziness (7%), dyskinesia (7%), erythema (6%), pruritus 
      (6%). Unified Parkinson's Disease Rating Scale II and III, Parkinson's Disease 
      Sleep Scale-2 and Pittsburgh Sleep Quality Index were unchanged. Numerical 
      improvements in 'off' time, awakenings and nocturias were observed. CONCLUSIONS: 
      Switch from pramipexole or ropinirole to rotigotine (up to 14 mg/24 h) was 
      feasible and possibly associated with some benefit.
FAU - Chung, Sun Ju
AU  - Chung SJ
AD  - University of Ulsan College of Medicine, Asan Medical Center, Department of 
      Neurology , Seoul , Republic of Korea.
FAU - Kim, Jong-Min
AU  - Kim JM
FAU - Kim, Jae Woo
AU  - Kim JW
FAU - Jeon, Beom Seok
AU  - Jeon BS
FAU - Singh, Pritibha
AU  - Singh P
FAU - Thierfelder, Stephan
AU  - Thierfelder S
FAU - Ikeda, Junji
AU  - Ikeda J
FAU - Bauer, Lars
AU  - Bauer L
CN  - Asia Pacific Rotigotine Switching Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01711866
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150406
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Benzothiazoles)
RN  - 0 (Indoles)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Thiophenes)
RN  - 030PYR8953 (ropinirole)
RN  - 46627O600J (Levodopa)
RN  - 83619PEU5T (Pramipexole)
RN  - 87T4T8BO2E (rotigotine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiparkinson Agents/*therapeutic use
MH  - Benzothiazoles/*therapeutic use
MH  - Drug Substitution
MH  - Female
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Levodopa/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
MH  - Pramipexole
MH  - Tetrahydronaphthalenes/*therapeutic use
MH  - Thiophenes/*therapeutic use
OTO - NOTNLM
OT  - Parkinson's disease
OT  - pramipexole
OT  - ropinirole
OT  - rotigotine transdermal system
OT  - safety
FIR - Kim, Jae Woo
IR  - Kim JW
FIR - Kim, Sang Jin
IR  - Kim SJ
FIR - Jeon, Beom Seok
IR  - Jeon BS
FIR - Sohn, Young-Ho
IR  - Sohn YH
FIR - Kim, Jong-Min
IR  - Kim JM
FIR - Kwon, Do Young
IR  - Kwon do Y
FIR - Chung, Sun Ju
IR  - Chung SJ
FIR - Lee, Ho-Won
IR  - Lee HW
FIR - Park, Mee Young
IR  - Park MY
FIR - Huang, Chin-Chang
IR  - Huang CC
FIR - Tsai, Chon-Haw
IR  - Tsai CH
FIR - Wu, Ruey-Meei
IR  - Wu RM
FIR - Sim, Siew Hung
IR  - Sim SH
FIR - Tan, Louis
IR  - Tan L
FIR - Tan, Eng King
IR  - Tan EK
FIR - Jacobs, Alan
IR  - Jacobs A
FIR - Gwynn, Matthews
IR  - Gwynn M
FIR - Gehi, Chandra
IR  - Gehi C
FIR - Goldstein, Mark A
IR  - Goldstein MA
FIR - Gamez, Jose
IR  - Gamez J
FIR - Fisher, Mark
IR  - Fisher M
EDAT- 2015/04/08 06:00
MHDA- 2015/09/12 06:00
CRDT- 2015/04/08 06:00
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 10.1517/14656566.2015.1030336 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2015 May;16(7):961-70. doi: 
      10.1517/14656566.2015.1030336. Epub 2015 Apr 6.